Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,065 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Conventional Cytogenetic Analysis of Solid Tumor Abnormalities: A 25-Year Review of Proficiency Test Results from the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee.
Vanderscheldon RK, Sukov WR, Gardner JA, Rehder CW, Levy B, Velagaleti GV, Toydemir RM, Tang G, Boles B, Cao Y, Mixon C, Zou YS, Astbury C, Tsuchiya KD, Peterson JF. Vanderscheldon RK, et al. Among authors: tsuchiya kd. Genes (Basel). 2024 Dec 17;15(12):1612. doi: 10.3390/genes15121612. Genes (Basel). 2024. PMID: 39766879 Free PMC article. Review.
Glioblastoma, IDH-wildtype manifesting as intracranial hemorrhage: A case report highlighting the clinical utility of digital polymerase chain reaction in integrated diagnoses.
Nikai Y, Satomi K, Saito K, Gomyo M, Matsushita Y, Kato K, Nagahama K, Isomura A, Hayashi A, Yamagishi Y, Sasaki N, Kobayashi K, Tsuchiya K, Nagane M, Ichimura K, Shibahara J. Nikai Y, et al. Among authors: tsuchiya k. Neuropathology. 2025 Jan 3. doi: 10.1111/neup.13025. Online ahead of print. Neuropathology. 2025. PMID: 39748727
Publisher Correction: Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
Okabe M, Yamamoto S, Shiokawa M, Hisamatsu T, Yamazaki H, Nakanishi R, Hamada K, Kitamoto H, Kuwada T, Uza N, Sakatani A, Fujii T, Ohno M, Matsuura M, Shibuya T, Ohmiya N, Ooi M, Hoshi N, Moriya K, Tsuchiya K, Yamaguchi Y, Kunisaki R, Takahara M, Takagi T, Takehara T, Hirai F, Kakimoto K, Esaki M, Nakase H, Kinjo F, Torisu T, Kanmura S, Narimatsu K, Matsuoka K, Hiraga H, Yokoyama K, Honzawa Y, Naganuma M, Saruta M, Kodama Y, Chiba T, Seno H. Okabe M, et al. Among authors: tsuchiya k. J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203-x. Online ahead of print. J Gastroenterol. 2024. PMID: 39729094 No abstract available.
Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study".
Kudo M, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M. Kudo M, et al. Among authors: tsuchiya k. Liver Cancer. 2024 May 6;13(6):671-673. doi: 10.1159/000539205. eCollection 2024 Dec. Liver Cancer. 2024. PMID: 39687035 Free PMC article. No abstract available.
3,065 results